Related references
Note: Only part of the references are listed.Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia
Giovanni Cazzaniga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Clinical peptide vaccination trials for leukemia patients
R. Casalegno-Garduno et al.
EXPERT REVIEW OF VACCINES (2011)
Melanoma vaccines: developments over the past 10 years
Oliver Klein et al.
EXPERT REVIEW OF VACCINES (2011)
Current status and future applications of cellular therapies for cancer
John Copier et al.
IMMUNOTHERAPY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Recent Developments in Cancer Vaccines
Karolina Palucka et al.
JOURNAL OF IMMUNOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Focus on Adoptive T Cell Transfer Trials in Melanoma
Liat Hershkovitz et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers
David B. Page et al.
IMMUNOTHERAPY (2010)
Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia
Misato Kikuchi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
Ralf Lutterbuese et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Biochemical signaling pathways for memory T cell recall
Donna L. Farber
SEMINARS IN IMMUNOLOGY (2009)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
The adaptive immune response to sporadic cancer
Gerald Willimsky et al.
IMMUNOLOGICAL REVIEWS (2007)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
Ettore Biagi et al.
HAEMATOLOGICA (2007)
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment:: data from the GMALL 06/99 and 07/03 trials
Thorsten Raff et al.
BLOOD (2007)
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
B Schlereth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Adoptive-cell-transfer therapy for the treatment of patients with cancer
ME Dudley et al.
NATURE REVIEWS CANCER (2003)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Qualitative differences between naive and memory T cells
M Berard et al.
IMMUNOLOGY (2002)
Share Paper
